longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Pharmaron

300759

43.751.39% ( +0.60 )
Delay Closed: Sep 17, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 46.93, within the reasonable range, cheaper than 27.01% of the time in the past 5 years, and the industry ranks 5/27, the industry Median 52.31.

46.93xP/E
¥43.75Stock price
¥0.93Earnings per share
46.93xP/E
Stock price¥43.75Earnings per share¥0.93

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
34.99x
Typical range
25.18x–52.35x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 52.31x
0135270405540

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 52.31x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
300759SZPharmaron
46.93x17.11%¥80.38B
301333SZR&G Pharma
50.26x20.98%¥6.04B
688755SHHanbon
40.96x--¥3.12B
301257SZClinPlus
52.31x--¥3.04B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.